Tripathy Talks Genomics, Targeted Treatments, and Smart Trial Designs in Breast Cancer

In Partnership With:

Partner | Cancer Centers | <b>The University of Texas MD Anderson Cancer Center</b>

In our exclusive interview, Debu Tripathy, MD, considers the biological and long-term outcome variability of HR-positive, HER2-negative breast cancer and details the research that is being done to develop personalized treatment approaches.

Welcome to a very special edition of OncLive On Air™! I’m your host today, Jessica Hergert.

OncLive On Air™ is a podcast from OncLive®, which provides oncology professionals with the resources and information they need to provide the best patient care. In both digital and print formats, OncLive® covers every angle of oncology practice, from new technology to treatment advances to important regulatory decisions.

Today, we had the pleasure of speaking with Debu Tripathy, MD, professor of medicine and chair of the Department of Breast Medical Oncology at The University of Texas MD Anderson Cancer Center, to shed light on the characteristics of hormone receptor (HR)–positive, HER2-negative breast cancer and opportunities for therapy with CDK4/6 inhibitors, PI3K inhibitors, and AKT inhibitors, among other agents.

In our exclusive interview, Tripathy considered the biological and long-term outcome variability of HR-positive, HER2-negative breast cancer and detailed the research that is being done to develop personalized treatment approaches.